OCUPHIRE PHARMA INC. - COMMON STOCK
1.2900
27-September-24 15:59:54
15 minutes delayed
Stocks
-0.0100
-0.77%
Today's range
1.2502 - 1.3050
ISIN
N/A
Source
NASDAQ
-
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
15 May 2023 08:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator
02 May 2023 08:30:00 By Nasdaq GlobeNewswire
-
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
25 Apr 2023 08:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
21 Apr 2023 08:00:00 By Nasdaq GlobeNewswire
-
30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting
23 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
16 Feb 2023 08:30:01 By Nasdaq GlobeNewswire
-
13 Feb 2023 08:00:00 By Nasdaq GlobeNewswire
-
25 Jan 2023 16:01:00 By Nasdaq GlobeNewswire
-
09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire
-
06 Dec 2022 06:00:00 By Nasdaq GlobeNewswire
-
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
21 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
07 Nov 2022 16:05:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
04 Nov 2022 16:30:00 By Nasdaq GlobeNewswire
-
02 Nov 2022 08:09:57 By Nasdaq GlobeNewswire
-
24 Oct 2022 08:56:52 By Nasdaq GlobeNewswire
-
Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
07 Oct 2022 07:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
06 Oct 2022 09:27:49 By Nasdaq GlobeNewswire
-
Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
29 Sep 2022 08:00:01 By Nasdaq GlobeNewswire
-
15 Sep 2022 07:00:01 By Nasdaq GlobeNewswire